arrow
返回

Developing a value proposition for high-sensitivity troponin testing

delete2018-02-01
delete9
PRE
AI
A
Andrew St John *
L
Louise Cullen
P
Paul Jülicher
C
Christopher P. Price
DOI:10.1016/j.cca.2017.12.007delete
delete原文链接
delete原文求助
delete分享
delete收藏
摘要

摘要

En 中文
Laboratories are looking for ways that they can identify and deliver value through their service rather than just provide high quality test results. One way to demonstrate value has been described in the form of a value proposition where the application of a laboratory test is described explicitly in terms of the process of care and the patient outcomes. We have applied this concept to the use of high sensitivity troponin assays for the assessment of patients with suspected acute coronary syndrome. From a previously described framework we use a checklist to describe the various steps in the complete intervention or clinical pathway, demonstrating how the test should be used, highlighting key evidence in the literature that supports the intervention and list some of the measures which can be used to assess how well the intervention is being adopted and implemented. While the value proposition concept is based on the foundations of evidence based medicine it also requires collaboration between the laboratory and other stakeholders including clinicians to ensure that appropriate resources are applied across the complete clinical pathway in order to ensure its effectiveness.
Keyword:
Diagnostics
Value proposition
Troponin
Acute coronary syndrome
Health economics
Cost-effectiveness
AI总结

AI总结

对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Clinica Chimica Acta 封面图
Clinica Chimica Acta
IF:
2.9
论文数:
1.6W
被引数:
2.1W

机构

U
university of oxford
学者数:
9.8W
论文数: 8.6W
被引数: 137
引用论文

引用论文

Case definitions for acute coronary heart disease in epidemiology and clinical research studies - A statement from the AHA council on epidemiology and prevention; AHA Statistics Committee; World Heart Federation Council on epidemiology and prevention; the European Society of Cardiology working group on epidemiology and prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute
err2003-11-18
err745
errOAAI
errLuepker, RV; Apple, FS; Christenson, RH; Crow, RS; Fortmann, SP; Goff, D; Goldberg, RJ; Hand, MM; Jaffe, AS; Julian, DG; Levy, D; Manolio, T; Mendis, S; Mensah, G; Pajak, A; Prineas, RJ; Reddy, S; Roger, VL; Rosamond, WD; Shahar, E; Sharrett, AR; Sorlie, P; Tunstall-Pedoe, H
err分享
err收藏
Current Evidence and Future Perspectives on the Effective Practice of Patient-Centered Laboratory Medicine
err2015-04-01
err59
errOAAI
errHallworth, Mike J.; Epner, Paul L.; Ebert, Christoph; Fantz, Corinne R.; Faye, Sherry A.; Higgins, Trefor N.; Kilpatrick, Eric S.; Li, Wenzhe; Rana, S. V.; Vanstapel, Florent
err分享
err收藏
err分享
err收藏
err分享
err收藏
Anatomy of a value proposition for laboratory medicine
err2014-09-01
err23
PREAI
errPrice, Christopher P.; St John, Andrew
err分享
err收藏
err分享
err收藏
ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells
err2012-01-01
err0
PREAI
errShyamal D Desai; Ryan E Reed; Julian Burks; Laurence M Wood; Ashok K Pullikuth; Arthur L Haas; Leroy F Liu; Jerome W Breslin; Sally Meiners; Surendran Sankar
err分享
err收藏
Leveraging the real value of laboratory medicine with the value proposition
err2016-11-01
err47
errOAAI
errPrice, Christopher P.; St John, Andrew; Christenson, Robert; Scharnhorst, Volker; Oellerich, Michael; Jones, Patricia; Morris, Howard A.
err分享
err收藏
From biomarkers to medical tests: The changing landscape of test evaluation从生物标志物到医学测试: 测试评估的变化
err2014-01-01
err144
PREAI
errHorvath, Andrea R.; Lord, Sarah J.; StJohn, Andrew; Sandberg, Sverre; Cobbaert, Christa M.; Lorenz, Stefan; Monaghan, Phillip J.; Verhagen-Kamerbeek, Wilma D. J.; Ebert, Christoph; Bossuyt, Patrick M. M.
err分享
err收藏
学者 查看更多内容